Spasticity — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for spasticity. 23 active patents protecting 3 drugs from 3+ originators. First major cliff: 2039. Daily refresh.

3
Approved drugs
23
Active US patents
68/100
Avg vulnerability
Annual revenue covered

Originators in Spasticity

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Roche) 21 patents Hikma 1 patents Pfizer 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating spasticity. Each bar = one year. Y-axis scaled to peak year (15 patents).

15
29
6
32
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Valium
diazepam
Generic (originally Roche) 21 67 2029-03-27
Skelaxin
METAXALONE
Pfizer 1 63 2039-07-29
Robaxin
METHOCARBAMOL
Hikma 1 75 2044-10-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12337061 Valium method of use 75 2032-06-13
12337061 Valium method of use 75 2032-06-13
12337061 Valium method of use 75 2032-06-13
12324852 Valium method of use 75 2032-10-16
12324852 Valium method of use 75 2032-10-16
12324852 Valium method of use 75 2032-10-16
12390439 Robaxin method of use 75 2044-10-09
12268664 Valium formulation 68 2029-03-27
12521400 Valium formulation 68 2029-03-27
12521400 Valium formulation 68 2029-03-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11918559 Skelaxin formulation 55 2039-07-29
8895546 Valium formulation 55 2029-03-27
8895546 Valium formulation 55 2029-03-27
8895546 Valium formulation 55 2029-03-27
11793786 Valium formulation 63 2029-03-27
11793786 Valium formulation 63 2029-03-27
11793786 Valium formulation 63 2029-03-27
11241414 Valium formulation 63 2029-03-27
11241414 Valium formulation 63 2029-03-27
11241414 Valium formulation 63 2029-03-27

Related